CN111019898A - Human malignant phylliform tumor cell line HJP-0320 and application thereof - Google Patents
Human malignant phylliform tumor cell line HJP-0320 and application thereof Download PDFInfo
- Publication number
- CN111019898A CN111019898A CN201910115538.XA CN201910115538A CN111019898A CN 111019898 A CN111019898 A CN 111019898A CN 201910115538 A CN201910115538 A CN 201910115538A CN 111019898 A CN111019898 A CN 111019898A
- Authority
- CN
- China
- Prior art keywords
- tumor
- hjp
- cell line
- phylliform
- tumor cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a human malignant phylloporphic tumor cell line HJP-0320, which is preserved in China center for type culture Collection with the preservation addresses as follows: china, Wuhan university, with the accession number C2018233. The invention also discloses a cell model for researching tumor generation and development mechanism of the human malignant phylliform tumor cell line HJP-0320 and application of the cell model in screening antitumor drugs. The human phylliform tumor cell line HJP-0320 is established from Chinese, has short establishing time and stable biological heredity, is lack of human malignant phylliform tumor cell lines in the market at present, and is taken as a research model to be greatly helpful for understanding the pathogenesis of Chinese phylliform malignant tumor patients.
Description
Technical Field
The invention relates to the technical field of tumor cell lines, in particular to a human malignant phyllodes tumor cell line HJP-0320 and application thereof.
Background
The breast phyllodes tumor is a rare breast tumor, which accounts for about 1 percent of the breast tumor, and the tumor grows quickly and is often expressed as a huge tumor; histologically, it is classified as benign, junctional, malignant; even benign leaf tumors recur, and malignant leaf tumors also undergo hematogenous metastasis. Chemotherapy and radiotherapy have uncertain therapeutic effects on leaf tumors, and the existing treatment method capable of reducing the recurrence and metastasis probability is enlarged surgical resection, but even if enlarged surgical resection is carried out, the local recurrence rate of the leaf tumors is still as high as 8-36%, and the blood-borne metastasis rate of malignant leaf tumors is as high as 22%.
At present, the mechanism that contributes to the malignant transformation of phyllodes is not clear. Existing molecular markers are also of limited value in predicting the biological behavior of tumors. Therefore, it is necessary to enhance the research on the malignant progression mechanism of the leaf tumor cells, and the method has important significance in suppressing the malignant progression of the leaf tumor and reducing the local recurrence, distant metastasis and mortality of the malignant leaf tumor. The establishment of reliable leaf-shaped tumor cell lines is urgent.
Disclosure of Invention
Based on the above problems, the present invention aims to overcome the defects of the prior art and provide a human malignant phyllodes tumor cell line HJP-0320 to fill the vacancy of the phyllodes tumor cell line derived from the current domestic and foreign populations.
In order to achieve the purpose, the technical scheme adopted by the invention comprises the following aspects:
in a first aspect, the invention provides a human malignant phyllo-tumor cell line HJP-0320, which is deposited in China Center for Type Culture Collection (CCTCC) at the following deposition addresses: china, Wuhan university, with the accession number C2018233.
In a second aspect, the present invention provides a cell model for studying the mechanism of tumorigenesis and development, said cell model being a cell line as described above.
Preferably, the tumor is a malignant tumor.
Preferably, the tumor is a breast phyllodes malignancy.
In a third aspect, the invention provides the application of the cell line HJP-0320 in screening of antitumor drugs.
Preferably, the tumor is a breast phylloid tumor.
In conclusion, the beneficial effects of the invention are as follows:
the human phylliform tumor cell line HJP-0320 is established from Chinese, has short establishing time and stable biological heredity, is lack of human malignant phylliform tumor cell lines in the market at present, and is taken as a research model to be greatly helpful for understanding the pathogenesis of patients with the Chinese phylliform tumor.
Drawings
FIG. 1 is a photograph of the human malignant phylloporphic tumor cell line HJP-0320 of the present invention under an optical microscope.
Detailed Description
The invention relates to the field of microbial animal cell lines, in particular to a human breast phylliform tumor cell line and an establishment method thereof. The human phyllodes tumor cell line HJP-0320 is derived from the right breast tumor of a 47-year-old female patient with malignant phyllodes tumor, is named as human phyllodes tumor malignant cell line HJP-0320, is preserved in a Chinese typical culture center, and has the preservation date of 2018, 12 months and 16 days; the preservation address is as follows: china, Wuhan university, with a preservation number of CCTCC NO: C2018233.
to better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments. Unless otherwise specified, the experimental methods in the present invention are all conventional methods. Unless otherwise specified, the concentrations of the reagents in the present invention are mass concentrations.
Example 1
The human phylliform tumor cell line HJP-0320 of the invention is obtained by the following method:
(1) the specimen collecting and storing method comprises the following steps: when the complete breast phylliform tumor is completely removed by operation, a sterile scalpel is used for cutting the center of the tumor tissue, and the tissue with vigorous and active hyperplasia is taken in a DMEM culture medium. The collection of the specimens is carried out under the guidance of a main scalpel and a pathologist, so that the influence on the diagnosis of pathological reports is prevented; when the specimen was not used for the subsequent operation, it was stored in DMEM medium at 4 ℃ and used for as long as 24 hours.
(2) Primary culture: the tissue was washed 3 times with PBS, mechanically sheared to the greatest extent, collagenase iii digestion (1mg/ml, Worthington) was added to a 50ml centrifuge tube containing DMEM/F12, tinfoil paper was protected from light, 37 degrees, 180 rpm, digested for 1 hour, centrifuged for 250g x 5min, PBS washed 1 time, inoculated and subcultured and observed cultured under the cell culture conditions: 37 ℃ and 5% (V/V) CO2The cell culture box adopts the following culture media: DMEM/F12 (Invitrogen); EGF (Peprotech,20 ng/ml); hydrocortisone (Sigma,0.5 mg/ml); insulin (Sigma,10 ug/ml); pen/strep (Invitrogen); the cell morphology of the cell line HJP-0320 during culture is shown in FIG. 1: long spindle, highly invasive mesenchymal cells, grow faster, their ER (-), PR (-), Her-2 (-); when the cells are passaged, the cells are digested by Tryple trypsin and are passaged according to the ratio of 1: 2.
(3) And (3) purifying cells: in order to extract primary phyllo-tumor cells from relatively pure interstitial components, specifically, after the cells are passaged for several times, the cells are passaged to a large culture dish according to the ratio of 1:10 to be cultured, cells with interstitial characteristics are observed and marked under a mirror, cells with peripheral epithelial characteristics are scraped under a sterile condition, washed by PBS for 3 times, and added with a fresh culture medium to be continuously cultured and passaged.
(4) Immortalizing primary cells: the HJP-0320 cell line successfully infects primary cells and can passage to 30 generations by infecting the immortalized virus SV40T, i.e., the immortalization is successful (the method is from abm).
Wherein the immortalization comprises the following specific steps:
1. culturing the packaging cells: before transfection, the lentivirus packaging cell 293T is recovered in advance and cultured in a 10cm cell plate, and 10ml of DMEM medium containing 10% (W/W) heat-inactivated Fetal Bovine Serum (FBS) is added to ensure that the cell fusion rate reaches 70-80% when the virus packaging is carried out. The cell culture conditions were the same as in the primary culture of step (2).
2. Preparing a lentivirus mixture:
2.1. transfection was carried out using LIP3000, adding 10ug of pLenti-SV40-TVector plasmid (from abm) and 10ug of lentiviral transfection packaging plasmid to 750ul of opti-mem, mixing well, and incubating at room temperature for 5 min. Simultaneously adding 80ul of LIP3000 transfection reagent into 750ul of opti-mem, mixing uniformly, and incubating for 5min at room temperature;
2.2. adding the LIP3000 transfection reagent mixed solution into the plasmid mixed solution, mixing uniformly, and incubating at room temperature for 15 min.
3. The prepared packaging cells 293T were replaced with 6ml of fresh medium, the lentivirus mixture was added and shaken well. Cells were at 5% (V/V) CO2Culturing at 37 deg.C for 48 h.
4. And (3) harvesting lentivirus: the medium was collected 48 hours after transfection, and the medium was filtered through a 0.45 μm filter to obtain a purified virus solution. The virus particles were collected by centrifugation at 10,000 Xg for 4 hours to obtain concentrated lentiviruses, which were stored in a freezer at-80 ℃.
5. Lentivirus infection:
5.1 inoculating 6-hole plate 6h before infection to ensure that the leaf-shaped tumor cells grow to about 30-40% of fusion density during infection;
5.2 taking the virus liquid stored in a refrigerator at minus 80 ℃ to room temperature for melting and mixing evenly;
5.3 according to the virus titer and the best MOI value determined by preliminary experiments, diluting the virus stock solution with virus dilution culture solution (10% FBS complete culture medium containing double antibody), preparing 0.8mg/mL Polybrene, infecting cells in a 6-well plate, adding 2mL of virus solution (containing 10ug/mL Polybrene) into each well, placing the virus supernatant in a refrigerator, and secondarily infecting in the afternoon;
and 5.4, removing virus liquid in the cells, adding the virus liquid into a complete culture medium incubator for incubation, carrying out passage after the cells grow full, synchronously culturing the uninfected cells and the infected cells for more than 30 passages, and selecting the cells with normal shapes for downstream detection.
Example 2 detection of viral expression
The expression level of the relevant immortalized gene (SV40T) introduced into the HJP-0320 cell line was determined by Q-PCR (quantitative real-time polymerase chain reaction, abbreviated as quantitative PCR). The gene primers used are shown in table 1 below.
TABLE 1 primer base sequences
Forward (Forward primer) | Reverse (Reverse primer) | |
GAPDH | AGAGCCTCGAGGAGAAGTTCC(SEQ ID NO.1) | ACTAGGGAGTCAAGGACGGG(SEQ ID NO.2) |
SV40T | GCCAGTACCGTGCCTTATCC(SEQ ID NO.3) | GAACCACTAGGCCCATAACCA(SEQ ID NO.4) |
The SV40T virus was introduced into the HJP-0320 cell line (accession number C2018233), and the results of overexpression detection of SV40T in the HJP-0320 cell line are shown in Table 2 below.
TABLE 2 expression results of SV40T in HJP-0320 cell line
Sample (I) | Introduction of Gene | ct value | Whether or not to express |
Control group | GAPDH | 14 | Is that |
Control group | SV40T | 35 | Whether or not |
Immortalizing group | GAPDH | 14 | Is that |
Immortalizing group | SV40T | 21.22 | Is that |
As is clear from the data in Table 2 above, SV40T gene (the introduction method is referred to as the virus infection step in example 1) was not expressed in the cells of the control group (wild-type breast phylloid tumor cells), while SV40T gene was successfully expressed in the cells of the immortalized group (HJP-0320), indicating that the HJP-0320 cells of the present invention were successfully immortalized.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (6)
1. The human malignant phyllo-tumor cell line HJP-0320 is characterized in that the cell line is preserved in China center for type culture Collection with the preservation addresses as follows: china, Wuhan university, with the accession number C2018233.
2. A cell model for studying the mechanism of development of tumorigenesis, said cell model being the cell line of claim 1.
3. The cell model of claim 2, wherein the tumor is a malignant tumor.
4. The cell model of claim 2 or 3, wherein the tumor is a breast phyllodes malignancy.
5. Use of the cell line HJP-0320 according to claim 1 for screening antitumor drugs.
6. The use of claim 5, wherein the tumor is a breast phyllode tumor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910115538.XA CN111019898B (en) | 2019-02-14 | 2019-02-14 | Human malignant foliar tumor cell line HJP-0320 and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910115538.XA CN111019898B (en) | 2019-02-14 | 2019-02-14 | Human malignant foliar tumor cell line HJP-0320 and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111019898A true CN111019898A (en) | 2020-04-17 |
CN111019898B CN111019898B (en) | 2023-07-21 |
Family
ID=70203438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910115538.XA Active CN111019898B (en) | 2019-02-14 | 2019-02-14 | Human malignant foliar tumor cell line HJP-0320 and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111019898B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113293133A (en) * | 2021-03-05 | 2021-08-24 | 中山大学孙逸仙纪念医院 | Human breast malignant phylliform tumor cell strain and application thereof |
CN113801849A (en) * | 2021-07-14 | 2021-12-17 | 中山大学孙逸仙纪念医院 | Human breast benign phylloid tumor cell strain BPT-0526 and application thereof |
CN114717190A (en) * | 2022-04-20 | 2022-07-08 | 中山大学孙逸仙纪念医院 | Human breast malignant phylliform tumor cell line BPT0713 and application thereof |
WO2024050858A1 (en) * | 2022-09-08 | 2024-03-14 | 中山大学孙逸仙纪念医院 | Malignant human breast phyllodes tumor cell line sysh-mpt-04 and use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060057716A1 (en) * | 2004-09-15 | 2006-03-16 | Chow Louis W | Human malignant cystosarcoma phyllodes derived mouse cell line |
US20150160193A1 (en) * | 2012-05-15 | 2015-06-11 | Diatech Oncology | Tumor cell isolation/purification process and methods for use thereof |
CN104745531A (en) * | 2015-02-13 | 2015-07-01 | 河南大学 | Method for establishing tumor multi-drug resistant cell mode and human breast cancer multi-drug resistant cell strain established by virtue of method |
CN108034636A (en) * | 2017-12-05 | 2018-05-15 | 浙江大学 | Human breast cancer cell line and application |
-
2019
- 2019-02-14 CN CN201910115538.XA patent/CN111019898B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060057716A1 (en) * | 2004-09-15 | 2006-03-16 | Chow Louis W | Human malignant cystosarcoma phyllodes derived mouse cell line |
US20150160193A1 (en) * | 2012-05-15 | 2015-06-11 | Diatech Oncology | Tumor cell isolation/purification process and methods for use thereof |
CN104745531A (en) * | 2015-02-13 | 2015-07-01 | 河南大学 | Method for establishing tumor multi-drug resistant cell mode and human breast cancer multi-drug resistant cell strain established by virtue of method |
CN108034636A (en) * | 2017-12-05 | 2018-05-15 | 浙江大学 | Human breast cancer cell line and application |
Non-Patent Citations (11)
Title |
---|
MICHAEL A.WARSO ET AL: "A Cell Line Derived From a Clinically Benign Phyllodes Tumor:Characterization and Implications", 《ANTICANCER RESEARCH》 * |
ROBERT H SHOEMAKER: "The NCI60 human tumour cell line anticancer drug screen", 《NAT REV CANCER》 * |
WALTER M. LEWKO ET AL: "Cultured breast cystosarcoma phylloides cells and applications to patient therapy", 《BREAST CANCER RESEARCH AND TREATMENT》 * |
刘小珍等: "肿瘤细胞原代培养与保存", 《中国肿瘤》 * |
刘广芝等: "SV40T基因介导的永生化对细胞生物学特性的影响", 《中原医刊》 * |
姜炬芳等: "人乳腺肿瘤原代细胞的分离培养", 《中国药物与临床》 * |
朴英实 等: "《分子病例生物学实验技术指南》", 31 May 2015, 人民军医出版社 * |
汪廷乐等: "人永生化细胞系模型建立的方法", 《上海口腔医学》 * |
纪洪媛: "乳腺叶状肿瘤病理研究进展", 《医学理论与实践》 * |
金岩 等: "《组织工程学原理与技术》", 30 June 2004, 第四军医大学出版社 * |
马中骥: "乳腺叶状囊肉瘤(综述)", 《国外医学肿瘤学分册》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113293133A (en) * | 2021-03-05 | 2021-08-24 | 中山大学孙逸仙纪念医院 | Human breast malignant phylliform tumor cell strain and application thereof |
CN113801849A (en) * | 2021-07-14 | 2021-12-17 | 中山大学孙逸仙纪念医院 | Human breast benign phylloid tumor cell strain BPT-0526 and application thereof |
CN113801849B (en) * | 2021-07-14 | 2023-11-07 | 中山大学孙逸仙纪念医院 | Human breast benign phylliform tumor cell strain BPT-0526 and application thereof |
CN114717190A (en) * | 2022-04-20 | 2022-07-08 | 中山大学孙逸仙纪念医院 | Human breast malignant phylliform tumor cell line BPT0713 and application thereof |
CN114717190B (en) * | 2022-04-20 | 2023-10-03 | 中山大学孙逸仙纪念医院 | Human breast malignant phylliform tumor cell line BPT0713 and application thereof |
WO2024050858A1 (en) * | 2022-09-08 | 2024-03-14 | 中山大学孙逸仙纪念医院 | Malignant human breast phyllodes tumor cell line sysh-mpt-04 and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111019898B (en) | 2023-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111019899B (en) | Human malignant foliar tumor cell line LJ-0429 and application thereof | |
CN111019898B (en) | Human malignant foliar tumor cell line HJP-0320 and application thereof | |
WO2019206341A1 (en) | Rab22a-noefs fusion gene line for diagnosis and/or treatment of osteosarcoma and application thereof | |
CN111019897B (en) | Human benign phylliform tumor cell line GLK-1010 and application thereof | |
CN114432452B (en) | Medicine for resisting esophageal squamous cell carcinoma | |
CN110106150B (en) | Preparation method and application of synovial sarcoma cell line hSS-005R | |
CN109486765B (en) | NF2-/-Method for establishing Schwann cell line of vestibular nerve sheath tumor and cell line thereof | |
CN114457158B (en) | Application of Hsa_circ_0006867 serving as esophageal cancer molecular target in preparation of medicines and kits | |
CN113980888B (en) | Pure suspension culture cell and application and preparation method thereof | |
CN114686486A (en) | Application of reagent for detecting MYOD1 gene expression quantity in preparation of osteosarcoma transformation rhabdomyosarcoma or osteosarcoma prognosis preparation | |
CN114790463A (en) | Construction method and application of monoclonal cell strain of stable transfection CRISPR/dCas9 system | |
CN113249328B (en) | Application of EpCAM in regulation and control of hepatic differentiation of human hepatic precursor cells | |
CN113801849A (en) | Human breast benign phylloid tumor cell strain BPT-0526 and application thereof | |
CN116042526B (en) | Normal human immortalized colon fibroblasts with P16 gene specific methylation | |
CN113293211B (en) | Application of HERV-H-targeting substance in tumors | |
CN116814551B (en) | Pancreatic cancer organoid culture solution, culture reagent combination and culture method | |
CN114324126B (en) | Method for changing early B cell differentiation | |
CN117384856B (en) | Immortalized COPD human bronchial epithelial cell strain, construction method and application thereof | |
CN116814552A (en) | Esophageal cancer metastasis and invasion cell model and application thereof | |
CN110042083B (en) | BHK-21 cell strain for stably expressing MAP3K8 protein and construction and application thereof | |
CN113913382B (en) | In-vitro culture method of money fish brain cells | |
CN117757749A (en) | Culture medium and culture method of kidney cancer primary cells | |
CN117106724A (en) | H3K27M mutant spinal glioma cell and culture method thereof | |
CN115747163A (en) | Human mammary gland boundary leaf-shaped tumor fluorescence labeling cell line and application thereof | |
CN116333992A (en) | Human breast malignant phylliform tumor cell line SYSH-MPT-03 and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Nie Yan Inventor after: Song Erwei Inventor after: Huang Hongyan Inventor before: Song Erwei Inventor before: Nie Yan Inventor before: Huang Hongyan |
|
GR01 | Patent grant | ||
GR01 | Patent grant |